| Trogarzo (ibalizumab IV) / Theratechnologies, TaiMed Biologics |
NCT03913195: Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection |
|
|
| Completed | 3 | 46 | US | ibalizumab-uiyk, Trogarzo | TaiMed Biologics Inc., Westat | HIV-1-infection | 10/22 | 10/22 | | |
NCT05890963: 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults |
|
|
| Recruiting | 1 | 20 | RoW | ART, antiretroviral therapy, 10E8.4/iMab, ibalizumab, VRC07-523LS, VRC01 variant | David Ho, Henry M. Jackson Foundation for the Advancement of Military Medicine, US Military HIV Research Program, National Institute of Allergy and infectious Diseases (NIAID)/Vaccine Research Center (VRC) | HIV-1-infection | 12/24 | 02/25 | | |
NCT02028819: Compassionate Use of Ibalizumab for the Treatment of HIV Infection |
|
|
| No Longer Available | N/A | | US | Dolutegravir Sodium Monohydrate, TIVICAY, Ibalizumab, TMB-355 | University of Colorado, Denver | Human Immunodeficiency Virus (HIV) | 02/14 | 02/14 | | |
NCT05495204: External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA |
|
|
| Completed | N/A | 141 | US | Ibalizumab, Regimens not containing ibalizumab | Epividian, Theratechnologies, FIECON | HIV-1-infection | 02/23 | 02/23 | | |
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab |
|
|
| Recruiting | N/A | 600 | US | No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment | Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research | HIV Infections, Multi-Antiviral Resistance | 06/25 | 12/25 | | |
